Orthopaedic professionals are no strangers to the tension between innovation and regulation. The recent $147 million verdict against Johnson & Johnson’s subsidiary Biosense Webster illustrates how anticompetitive contracting practices can restrict access to care, delay the adoption of lower-cost technologies, and compromise ethical decision-making in clinical settings. While the case focused on cardiac catheters, the implications apply across device-heavy specialties, including orthopaedics.
The backstory: Catheters, contracts, and closed doors
Case Overview: Innovative Health won an antitrust lawsuit against Biosense Webster (a Johnson & Johnson company).
Key Issue: J&J used exclusive contracts and bundling to block hospitals from accessing FDA-cleared, lower-cost reprocessed catheters.
Legal Outcome: The jury found these tactics violated antitrust law by eliminating competition and driving up prices.
Wider Implications: The verdict sets a precedent. Dominant market players can face legal consequences for excluding safe, cost-effective products.
Why orthopaedics should pay attention
Orthopaedics has faced similar procurement structures for years. From hip and knee implants to biologics and trauma hardware, product selection is frequently shaped by bundled payment programs and exclusive supply contracts. These agreements are often negotiated at the administrative level, sidelining surgeons who are best positioned to evaluate device performance and clinical fit.
The use of exclusivity clauses and volume-based incentives in orthopaedic contracting can restrict access to emerging alternatives, including reprocessed devices or products from smaller manufacturers. Hospitals then pass over potential cost savings and innovation in favor of familiar vendors who offer purchasing efficiency through exclusivity. These practices mirror the same market-lock behaviors seen in the Biosense Webster case.
The ethical undercurrent: Autonomy, equity, and evidence
When a surgeon is unable to select a device that is FDA-cleared, clinically supported, and preferred based on experience, the principle of professional autonomy is compromised. The core ethical responsibility to recommend what is best for the patient becomes subordinated to contract terms that may have been negotiated without clinician input.
The consequences of this structure disproportionately affect hospitals serving lower-income or rural populations. These institutions are more likely to accept restrictive contracts that offer short-term savings or bundled rebates, even if it limits their ability to consider cost-saving alternatives in the long term. In orthopaedics, where implant pricing is a major cost driver, these restrictions directly impact procedure accessibility and equity in patient care.
A market that resists disruption
Innovative Health’s business model challenged a high-margin product by offering a lower-cost, reprocessed option that met regulatory standards. Rather than compete on performance or value, Biosense Webster allegedly pursued strategies to exclude the product from hospital consideration entirely. The verdict made clear that anticompetitive exclusion, even in the form of routine contracting practices, can be subject to legal action.
This is not unique to cardiology. In orthopaedics, disruptive device companies often find it difficult to gain traction within hospital systems, even when they offer evidence-backed alternatives. Barriers include closed formularies, lack of access to value analysis committees, and vendor relationships that prioritize continuity over value. These dynamics suppress innovation and reduce competitive pressure on incumbent device makers.
Action points for orthopaedic professionals
Orthopaedic teams and hospital administrators can take practical steps to address procurement risks and uphold ethical and clinical standards. Key actions include:
- Promote transparency in purchasing agreements by:
- Requesting full disclosure of exclusivity terms in vendor contracts.
- Asking how reprocessed or alternative devices were evaluated, and why they were excluded.
- Ensure clinician representation in device selection by:
- Structuring value analysis committees to include input from active surgical teams, not just administrative stakeholders.
- Advocate for evidence-based decision-making by:
- Supporting cost-effectiveness studies that include reprocessed or lower-cost alternatives when available.
- Support device reprocessing when appropriate by:
- Ensuring FDA clearance and strong performance data back these options.
- Recognizing that exclusions often stem from pricing structures, not performance concerns, that favor dominant suppliers.
By actively participating in procurement processes, clinical teams help ensure that both patient care and fiscal responsibility remain top priorities.
What this verdict really means
The verdict against Biosense Webster demonstrates that legal frameworks are starting to catch up to long-standing anticompetitive behavior in healthcare contracting. But lawsuits alone will not prevent similar dynamics from unfolding in orthopaedics. The real power to protect patient care and professional judgment lies in engaging directly with the structures that determine what devices are available to use.
Ethical care depends on access to choices that are evidence-based and value-aligned. When procurement systems limit those choices due to market control, clinicians must intervene. Not only to protect autonomy, but to ensure innovation and patient access are not collateral damage.
The next verdict could involve spinal instrumentation or joint replacement systems rather than cardiac catheters. The pressures are already present. It is up to orthopaedic professionals to act before access is reduced to what fits inside a contract.
Sources
J&J subsidiary fined $147M for limiting catheter access
Policies To Combat Anticompetitive Practices in Health Care
Preventing Anticompetitive Contracting Practices in Healthcare Markets
